更新于：2024-11-01

金葡球菌金属蛋白酶 x MMPs

更新于：2024-11-01

基本信息

关联

项与金葡球菌金属蛋白酶 x MMPs 相关的药物

SRD-441

靶点

MMPs x 金葡球菌金属蛋白酶

作用机制

MMPs抑制剂 [+1]

在研机构-

原研机构

Serentis, Inc.

在研适应症-

非在研适应症

特应性皮炎

最高研发阶段无进展

首次获批国家/地区-

首次获批日期1800-01-20

项与金葡球菌金属蛋白酶 x MMPs 相关的临床试验

ACTRN12622001421729 / Completed临床1期

A pivotal in vivo bioequivalence study comparing two formulations of 21-acetoxyl group-11 beta-hydroxy-6 Alpha-Methyls-17-propiono Oxy-1,4-pregnen diethylene-3,20-diketone ointment, using the appropriate dose duration (ED50) calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.

开始日期2023-01-18

申办/合作机构

Zenith Technology Corp. Ltd.

NCT01531517 / Terminated临床3期

Study of the Efficacy of Topical Application of Royal Jelly and Panthenol (PedyPhar® Ointment) on the Diabetic Foot Ulcers, An Open Label, Randomized, Non-placebo-controlled Study

Clinical Trial Phase III-b
Study Sponsor:
European Egyptian Pharmaceutical Industries
Sample Size:
120 patients (60 per arm)
Study Population:
Patients with Diabetic foot ulcer of any stage after proper surgical treatment - if needed. Those patients will be recruited from patients attending the Diabetic foot Center at Faculty of Medicine - Alexandria University and the outpatient clinic at Faculty of Medicine, Cairo University.
Recruitment Period: 9 months
Dose application: thick layer of 2-3 mm applied to the dressing then dressing applied to the ulcer.
Endpoints: Complete healing of the ulcer OR 5 months of application of the ointment whichever comes first

开始日期2011-07-01

申办/合作机构

European Egyptian Pharmaceutical Industry

100 项与金葡球菌金属蛋白酶 x MMPs 相关的临床结果

登录后查看更多信息

100 项与金葡球菌金属蛋白酶 x MMPs 相关的转化医学

登录后查看更多信息

0 项与金葡球菌金属蛋白酶 x MMPs 相关的专利（医药）

登录后查看更多信息

项与金葡球菌金属蛋白酶 x MMPs 相关的文献（医药）

2019-04-30·mBio

Protease-Mediated Growth of Staphylococcus aureus on Host Proteins Is opp3 Dependent

Article

作者: Fey, Paul D. ; Nuxoll, Austin S. ; Kielian, Tammy ; Lehman, McKenzie K. ; Yamada, Kelsey J. ; Carson, Steven D.

Staphylococcus aureus has the ability to cause infections in a variety of niches, suggesting a robust metabolic capacity facilitating proliferation under various nutrient conditions. The mature skin abscess is glucose depleted, indicating that peptides and free amino acids are important sources of nutrients for S. aureus . Our studies have found that mutations in both pyruvate carboxykinase and glutamate dehydrogenase, enzymes that function in essential gluconeogenesis reactions when amino acids serve as the major carbon source, reduce bacterial burden in a murine skin abscess model. Moreover, peptides liberated from collagen by host protease MMP-9 as well as the staphylococcal protease aureolysin support S. aureus growth in an Opp3-dependent manner under nutrient-limited conditions. Additionally, the presence of peptides induces aureolysin expression. Overall, these studies define one pathway by which S. aureus senses a nutrient-limiting environment and induces factors that function to acquire and utilize carbon from host-derived sources.

2010-12-01·Allergy1区 · 医学

The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study

1区 · 医学

Article

作者: M. Kadurina ; M. Worm ; T. Bieber ; R. Tansley ; K. Thaci ; M. Duffy ; N. Tsankov ; R. Yankova ; S. Reitamo ; T. Luger ; A. Enk ; R. Foelster Holst

To cite this article: Foelster Holst R, Reitamo S, Yankova R, Worm M, Kadurina M, Thaci K, Bieber T, Tsankov N, Enk A, Luger T, Duffy M, Tansley R. The novel protease inhibitor SRD441 ointment is not effective in the treatment of adult subjects with atopic dermatitis: results of a randomized, vehicle‐controlled study. Allergy 2010; 65: 1594–1599.AbstractBackground: There is evidence that excessive protease activity in the skin is an important factor in the development of atopic dermatitis. SRD44 is a topically formulated novel protease inhibitor that selectively inhibits Staphylococcal‐derived aureolysin and matrix metalloproteinases (MMPs).Methods: This was a double‐blind, vehicle‐controlled randomized trial conducted in thirteen hospital dermatology outpatient clinics in Germany (9), Bulgaria (3) and Finland (1). Ninety‐three out of 103 screened adult subjects with confirmed atopic dermatitis affecting ≤20% of body surface area, with an IGA score of 2 or 3 at randomization were randomized following a washout period to either SRD441 ointment or matching vehicle twice daily for 28 days. The primary efficacy endpoint was the clearance of Atopic dermatitis (AD score of 0 or 1 IGA) at Day 21. Secondary endpoints included measures of SCORing Atopic Dermatitis, pruritus self‐assessment, rescue medication use and occurrence of new exacerbations. A range of safety and tolerance endpoints were included.Results: There were no significant treatment differences in IGA success rates at Day 21 (SRD441 ointment, 11.1%; vehicle ointment, 12.5%; P = 1.000). Evaluation of secondary efficacy variables revealed no clinical or important statistical differences between treatment groups. Eighteen subjects (19.4%) discontinued the study drug because of an AE (seven subjects [15.6%] in the SRD441 group and 11 subjects [22.9%] in the vehicle group). Twenty‐seven subjects (60.0%) in the SRD441 group and 34 subjects (70.8%) in the vehicle group reported an adverse event (AE).Conclusions: SRD441 ointment did not demonstrate efficacy in the treatment of atopic dermatitis raising questions on the effectiveness of MMPs as a target for the treatment of atopic dermatitis. NCT00882245.